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Abstract
Background: The tablet formulation of ritonavir-boosted lopinavir (LPV/r; Kaletra®) has many
advantages over the soft gel capsule (SGC) formulation, including lower pill count, no refrigeration
requirement, and no dietary restrictions. These advantages may help improve patient compliance
and therefore increase adherence to treatment. However, there are limited data regarding patient
preferences and only recently was the comparative efficacy and tolerability data of LPV/r SGC
versus tablet formulation presented at an international conference. To address this deficit, we
conducted a market research survey to assess potential tolerability benefits, patient satisfaction,
changes in adherence, and formulation preference in patients switching from SGCs to the tablet
formulation. Data from 332 patients who switched from LPV/r SGCs twice-daily (BID) to tablets
BID and 41 patients who switched from LPV/r SGCs BID or once daily (QD) to tablets QD were
analyzed.
Results: Switching from SGCs to a tablet formulation of LPV/r was associated with increased
patient satisfaction, tolerability and self-reported adherence to treatment; gastrointestinal side
effects were reduced. In addition, respondents indicated that they preferred the tablet formulation
to the SGC.
Conclusion: The LPV/r tablet formulation provides HIV-infected patients with multiple benefits
over the SGC in terms of tolerability and convenience. Additional assessments to further define
the tolerability profile of the LPV/r tablet, including studies using once-daily dosing, are warranted.
Introduction
Lopinavir/ritonavir (LPV/r, Kaletra®), a co-formulation of
lopinavir (LPV) and ritonavir (RTV), is a protease inhibi-
tor (PI) used in the treatment of HIV infection. The low
dose of RTV in the LPV/r formulation increases LPV expo-
sure by decreasing metabolism of LPV via inhibition of
cytochrome P450 3A. RTV concentrations achieved are
below therapeutic concentrations. LPV/r, dosed at 400/
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100 mg in the form of three soft gel capsules (SGCs) BID,
has been shown to provide sustained virological response
(over seven years) as well as excellent immunological
responses in 61% of patients, with an on-treatment
response rate of 95% (HIV RNA < 50 copies/mL) [1]. In
addition, no primary PI resistance mutations or thymi-
dine analog mutations were observed during the seven
years of this study.
The original formulation of LPV/r was SGCs because the
active ingredients are poorly soluble and have poor bioa-
vailability when administered as an unformulated solid.
While SGCs have been widely used in the US and else-
where, there are some significant limitations:
￿ Pill count is high, requiring six capsules for the standard
daily dose (LPV/r 800/200 mg).
￿ Similar to RTV capsules, LPV/r SGCs exposed to high
temperatures are susceptible to softening and clumping
and may become impossible to separate without break-
ing, which may result in loss of drug and subsequently
inadequate drug exposure [2]. LPV/r SGCs must be refrig-
erated before dispensing to the patient and stored at room
temperature by the patient.
￿ The SGCs must be taken with food, creating the poten-
tial for inter- and intra-patient variability.
￿ The SGCs are associated with short to medium-term gas-
trointestinal (GI) side effects, mostly nausea, vomiting,
and diarrhea.
Several of these limitations are overcome with the recent
reformulation using melt extrusion technology. The tablet
formulation of LPV/r is bioequivalent to the SGC formu-
lation at a dose of 800/200 mg with reduced pharmacok-
inetic variability [3]. The LPV/r tablet formulation is
associated with a significantly reduced food effect, in that
increasing meal calories and fat content does not signifi-
cantly affect Cmax and AUC. The tablet formulation is also
significantly more bioavailable than the SGC formulation
when taken in a fasted state, which allows the flexibility to
dose LPV/r tablets with or without food. Furthermore, the
bioavailability of LPV is unaffected by acid-reducing
agents irrespective of whether the SGC or tablet formula-
tion is taken [4].
LPV/r was the first co-formulated antiretroviral to be for-
mulated as a tablet by melt extrusion. This technology
produces a solid dispersion (or solid suspension)
whereby the LPV/r molecules are uniformly distributed
throughout a hydrophilic polymeric matrix. This ensures
that the drug is released at a consistent rate in the GI tract
and allows for adequate bioavailability (previously
unachievable with traditional tablet formulations).
Advantages of the tablet formulation include a lower pill
count (four tablets versus six SGCs per day), no refrigera-
tion requirement, and no dietary restrictions.
The effectiveness of antiretroviral therapy (ART) depends
on treatment efficacy as well as patient adherence. Barriers
to adherence include adverse drug effects, pill count, dos-
ing frequency, dietary/fluid requirements and the need for
refrigerated storage. The LPV/r tablet formulation
addresses some of these barriers and may improve treat-
ment adherence.
There are limited data regarding patient preferences and
only recently at the Conference on Retroviruses and
Opportunistic Infections 2008 was the comparative effi-
cacy and tolerability of LPV/r SGC vs. tablet formulation
presented [5]. In this study, we report the results of a mar-
ket research survey, which was designed to assess the dif-
ferences in tolerability benefits, patient satisfaction,
changes in adherence, and formulation preference in
patients switching from LPV/r SGCs to tablets.
Methods
The survey was a self-administered written questionnaire
completed by patients at baseline and after switching
from LPV/r SGCs to tablets. Patients were required to have
a minimum of four weeks' experience taking each formu-
lation prior to filling out each survey. Surveys were distrib-
uted with the help of 52 participating physicians across 20
states plus D.C. and completed by patients in their doc-
tors' offices/clinics while waiting for their regularly sched-
uled appointments. Staff at the physicians' offices were
instructed to maintain patient privacy by having respond-
ents insert completed surveys into envelopes before
returning them; the staff then mailed them to the research
organization managing the project. Physicians received an
honorarium for each completed survey that was received
by the research organization. Packets of pre- and post-
switch questionnaires (both English and Spanish ver-
sions), with instructions for their distribution, were sent
to physicians in early October 2005. The deadline for
returning baseline surveys was May 2006.
Questionnaire design
Surveys were designed by Abbott Marketing Research.
Additional input from advisors was used to attain an
appropriate language and reading level (grade 5) for
patients. The majority of questions were identical in the
baseline and follow-up surveys for a longitudinal pre-ver-
sus post-switch analysis. Five comparative questions were
added to the follow-up questionnaire so that respondents
could make a direct assessment of SGCs versus tablets.
Statistical analysis
The Student's t-test was used for the analysis of continu-
ous data; nominal data were analyzed using Chi-squaredAIDS Research and Therapy 2008, 5:21 http://www.aidsrestherapy.com/content/5/1/21
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and Fisher's exact tests. While no power calculation was
completed, the sample size is large, including over 300
respondents.
Results
Patient demographics
The demographics of survey respondents are shown in
Table 1. There was a predominance of males and the
majority of respondents were over 35 years of age. More
than 80% of the respondents had received ART for more
than one year, received LPV/r SGCs for more than one
year, and received tablets for less than three months. All
respondents in the analysis had received SGC and tablet
formulations for at least four weeks each.
Improved tolerability and fewer side effects
Patients switched from SGCs BID to tablets BID
Three hundred and thirty-two patients who completed
linked questionnaires (pre- and post-switch) had
switched from SGCs BID to tablets BID. Before switching
to the tablet formulation, 60% of respondents reported
that they were "very satisfied" or "extremely satisfied"
with their treatment. This proportion increased to 80% (p
< 0.05) after these respondents switched to tablets BID.
There was also a significant increase in the proportion of
respondents describing the tolerability of their treatment,
with respect to side effects, as "great" or "pretty good"
when they switched from SGCs BID to tablets BID (63%
vs. 84%; p < 0.05) [Figure 1].
Respondents reported a significant improvement in
diarrhea after switching from SGCs to tablets; 82% of
respondents reported either no diarrhea or an improve-
ment in diarrhea after this switch. This included a 21%
increase in the proportion of respondents who indicated
no or rare diarrhea (p < 0.05). Only 3% of respondents
reported "severe" diarrhea while receiving the tablet for-
mulation compared with 12% receiving SGCs (p < 0.05).
Antidiarrheal use (3+ times per week) was reduced by half
after respondents switched to the tablet formulation (p <
0.05).
Significantly fewer respondents reported bloating, pain,
or gas in the stomach when they were switched to the tab-
let formulation, and those who did reported diminished
frequency: an additional 12% of respondents indicated
no occurrence or rare occurrence (p  < 0.05). Only 5%
reported "severe" episodes of bloating, pain, or gas in the
stomach after the switch to the tablet formulation, com-
pared with 8% when receiving the SGC formulation (p <
0.10).
Patients switched from SGCs BID or QD to tablets QD
Forty-one patients who completed pre- and post-switch
questionnaires had switched from SGCs BID (n = 20) or
QD (n = 21) to tablets QD. Before switching, 73% of
respondents were "very satisfied" or "extremely satisfied"
with their treatment; 64% rated tolerability, with respect
to side effects, as "great" or "pretty good". After switching
to tablets QD, 90% of respondents were "very satisfied" or
"extremely satisfied" with their treatment and 89% rated
tolerability of treatment as "great" or "pretty good" [Fig-
ure 1]. This represented an increase of 17% in patient sat-
isfaction (p < 0.05) and an increase of 26% for tolerability
(p < 0.05).
In the 20 respondents who switched from SGCs BID to
tablets QD, there was a 33% absolute increase in the
number who were "extremely satisfied" with their treat-
ment (from 30% pre-switch to 63% post-switch; p < 0.05).
Table 1: Respondent demographics
% Patients switching from SGCs BID to Tablets 
BID (%)
Patients switching from SGCs BID or QD to 
Tablets QD (%)
Male/Female 85/15 76/24
Age:
> 45 years 46 34
35–44 years 41 39
< 35 years 13 27
Duration of antiviral therapy
≥ 5 years 59 41
1–5 years 31 49
< 1 year 10 10
Duration of LPV/r therapy
SGC > 1 year 82 80
Tablet < 3 months 89 81AIDS Research and Therapy 2008, 5:21 http://www.aidsrestherapy.com/content/5/1/21
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For those switching from SGCs QD to tablets QD, there
was a 43% absolute increase in the proportion of respond-
ents who were "extremely satisfied" (from 14% pre-switch
to 57% post-switch; p < 0.05). There was also a significant
increase in the proportion of respondents who had "pretty
good" or "great" tolerability when switched to tablets QD:
a 24% absolute increase for those switching from SGCs
BID to tablets QD (from 70% pre-switch to 94% post-
switch; p < 0.05) and a 29% absolute increase for those
switching from SGCs QD to tablets QD (from 56% pre-
switch to 85% post switch; p < 0.05).
Overall, GI side effects improved after respondents were
switched to the LPV/r tablet formulation. After switching
from SGCs BID or QD to tablets QD, 78% of respondents
reported no diarrhea or had improvements in diarrhea;
more respondents who had switched from SGCs QD
(81%) than from SGCs BID (74%) reported improve-
ments. Reports of bloating, pain, or gas in the stomach
also decreased when respondents were switched from
SGCs to tablets, and the prevalence of nausea decreased
from 27% to 5% (p < 0.05). There were no "severe" epi-
sodes of diarrhea, nausea, and bloating/gas with the tablet
formulation compared with 0%, 8% and 6%, respectively,
with the SGC formulation. The need for antidiarrheal
medications was decreased; 80% of respondents reported
rare or no use with tablets compared to 56% with SGCs (p
< 0.05).
Greater self-reported adherence
Patients switched from SGCs BID to tablets BID
After patients switched from SGCs to tablets, the mean
number of self-reported missed doses per week decreased
from 1.25 to 0.71 (p < 0.05), equivalent to an improve-
ment in adherence from 91% to 95%. In addition, more
respondents indicated "not missing doses in the last
week" after switching to the tablet formulation. Taking
fewer pills per dose than prescribed was reported for 5%
of SGC doses and only 1% of tablet doses (p < 0.05), with
no differences between ethnic groups.
Significantly fewer respondents cited "avoiding side
effects", "ran out", and "didn't have food" as reasons for
non-adherence (p < 0.05) [Figure 2].
Tolerability reported by respondents switched to tablets BID or QD Figure 1
Tolerability reported by respondents switched to tablets BID or QD.AIDS Research and Therapy 2008, 5:21 http://www.aidsrestherapy.com/content/5/1/21
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Patients switched from SGCs BID or QD to tablets QD
The mean number of self-reported missed doses per week
decreased from 0.49 to 0.24 after patients were switched
from SGCs BID or QD to tablets QD, equivalent to an
improvement in adherence from 93% to 97%. Taking
fewer pills per dose than prescribed was reported for 2.1%
of SGC doses and 0.4% of tablet doses, with no differ-
ences between ethnic groups. A greater proportion of
respondents indicated "not missing doses in the last
week" after switching to tablets (90% on tablets vs. 75%
on SGCs). "Avoiding side effects" was cited by 5% of
respondents receiving SGCs as the reason for non-adher-
ence; when these patients switched to tablets, this reason
was no longer cited.
Patients prefer the tablet to the SGC
Patients switched from SGCs BID to tablets BID
Eighty-eight percent of respondents who switched from
SGCs BID to tablets BID preferred the tablet to the SGC
formulation, 9% had no preference, and the remaining
3% preferred the SGC.
Benefits of the tablet formulation over the SGC that the
respondents "liked" were: "don't need to refrigerate"
(67%), "fewer pills" (61%) and "don't have to take with
food" (41%).
Respondents were asked to rate their quality of life over
the last four weeks as "very bad, could hardly be worse",
"pretty bad", "good and bad parts about equal", "pretty
good" or "very well, could hardly be better". A large pro-
portion (73%) of respondents reported better quality of
life when taking the tablet; only 2% of respondents
reported a worse quality of life. There was also a signifi-
cant shift in respondents reporting quality of life that had
"good and bad parts about equal" to "pretty good" after
switching to the tablet formulation (21% and 48% before
switching, to 14% and 58% after switching, respectively; p
< 0.05).
Patients switched from SGCs BID or QD to tablets QD
Ninety-three percent of respondents who switched from
SGCs BID or QD to tablets QD preferred the tablet to the
SGC; 5% had no preference between the two formulations
and 2.5% preferred the SGC. Benefits of the tablet that
were "liked" by the respondents included: "once daily
dosing" (73%), "fewer pills" (73%), "don't have to take
with food" (68%) and "don't need to refrigerate" (65%).
Reasons for non-adherence in patients switched from SGCs BID to tablets BID Figure 2
Reasons for non-adherence in patients switched from SGCs BID to tablets BID.
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Quality of life over the last four weeks (rated by respond-
ents as "very bad, could hardly be worse", "pretty bad",
"good and bad parts about equal", "pretty good" or "very
well, could hardly be better") was improved when
respondents switched to the tablet formulation: 73% of
respondents reported an improvement and 2% reported
worsening with tablets dosed QD. An additional 12% of
respondents reported that they were "very well, could
hardly be better"; these respondents had previously
reported "good and bad parts about equal" and "pretty
good".
Ethnic differences
Data from the 332 patients who switched from SGCs BID
to tablets BID were analyzed according to ethnicity.
Twenty percent of respondents were Hispanic, 37% were
Black, 41% were Caucasian, and 2% were other ethnici-
ties.
The proportions of respondents indicating better side
effects with the tablet formulation were similar: 74% of
Caucasian, 85% of Black, and 76% of Hispanic respond-
ents. Differences among ethnic groups in reductions of
the frequency and severity of diarrhea are shown in Table
2; there was significant improvement in all groups. There
was also a trend for a decrease in antidiarrheal use; how-
ever, this only reached statistical significance in the Cau-
casian group (RR 0.72, SGC vs. tablet; p < 0.05).
A similar proportion of each ethnic group preferred the
tablet over the SGC (86%–89%), experienced "great" to
"pretty good" tolerability (82%–87%), and felt "very sat-
isfied" or "extremely satisfied" (79%–85%) with their
treatment. In addition, the rank order of cited tablet ben-
efits was the same across ethnic groups: "don't need to
refrigerate" > "fewer pills" > "don't have to take with
food". Significantly more SGC doses were taken without
food by Black respondents (21%) than Caucasians (12%),
p < 0.05.
The Caucasian group showed a high adherence rate on
SGCs (95%), leaving little room for improvement when
switched to tablets. Hence, the 96% adherence rate after
switching was not statistically significant. However, mean
weekly adherence rates did significantly improve in His-
panic (from 89% on SGCs to 96% on tablets; p < 0.05)
and Black respondents (from 88% on SGCs to 93% on
tablets; p < 0.05), who had lower mean adherence rates on
SGCs compared with Caucasians. A significant improve-
ment in complete adherence (defined as "not missing
doses in the last week") was observed in Hispanic
respondents (from 55% on SGCs to 72% on tablets; p <
0.05). On SGCs, significantly more Black respondents
(18%) than Caucasians (5%) indicated missing doses in
an attempt to avoid adverse effects. A comparison of the
ethnic groups using the tablet formulation did not show
any difference in missing doses in an attempt to avoid
adverse effects.
The number of doses missed in an attempt to avoid
adverse events was significantly reduced with switching
from SGC to tablets in Black and Hispanic respondents (p
< 0.05), with a non-significant decrease also noted for
Caucasians.
Discussion
In this study, pre- and post-switch patient surveys revealed
that the new tablet formulation of LPV/r is preferred over
SGC formulation, is better tolerated, has fewer side effects,
and is associated with greater adherence than the original
SGC formulation. These results support the data from
three studies that examined switching patients from LPV/
r SGC to tablet formulation. The first study involved indi-
gent AIDS patients and demonstrated that four weeks fol-
lowing the formulation switch there were greater patient
preference and satisfaction with LPV/r tablet, and signifi-
cant improvements in bowel habits that were maintained
through Week 12. There was a positive impact on subjects'
overall well-being, as measured by Global Condition
Improvement Questionnaire; however, the positive
changes in other quality of life measures (MOS-HIV PHS,
MOS-HIV MHS, ASDM, and CES-D) were not statistically
significant [6]. The second study was a sub-study of the
IMANI-2 LPV/r single agent trial. The key findings were a
Table 2: Ethnic differences in diarrheal side effects in respondents switching from BID SGCs to BID tablets
BID Respondents (n = 332) White (n = 136) Black (n = 123) Hispanic (n = 67)
Relative Risk (Tablets vs. SGCs)
Antidiarrheal use (more than "rarely use") 0.73* 0.72* 0.95 0.65
Diarrhea frequency 3+ per week 0.60* 0.68* 0.52* 0.39*
Respondent self-defined "severe" diarrhea 0.28* 0.47* 0.13* 0.17*
Proportion of respondents (Tablets vs. SGCs)
Respondent self-defined "severe" diarrhea 3.3% vs. 11.7%* 7% vs. 15%* 1% vs. 8%* 2% vs. 12%*
* p < 0.05AIDS Research and Therapy 2008, 5:21 http://www.aidsrestherapy.com/content/5/1/21
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reduction or elimination of diarrheal adverse events,
improved general health and ability to function in role at
work or in the home, improved self-reported ease of tak-
ing medication, and high satisfaction and preference for
LPV/r tablet formulation [7]. The third study evaluated
improvements in quality of life associated with switching
from LPV/r SGC to tablet in an African American cohort.
The study showed 96% of patients preferred the LPV/r tab-
let formulation, and modest improvements in general
health, mental health and role function as measured by
MOS-HIV. The majority of patients indicated their quality
of life was improved because of a lack of need to refriger-
ate tablets (80%), fewer pills (76%), and the removal of
food restrictions (60%) [8].
The majority of survey respondents (89%) in the current
analysis had been switched from LPV/r 400/100 mg SGC
BID to tablets BID. There were significant increases in
patient satisfaction and tolerability after the switch to the
tablet formulation. There were also improvements in the
proportion of respondents reporting diarrhea. Fewer
respondents reported severe diarrhea with a significant
reduction in the frequency of antidiarrheal use and side
effects of bloating, pain, or gas in the stomach.
A smaller proportion of survey respondents (11%) had
switched to a QD tablet regimen, either from LPV/r 800/
200 mg SGC QD or 400/100 mg SGC BID. In 2005, the
FDA approved QD dosing of LPV/r 800/200 mg in treat-
ment-naïve adults. The approval was based on an analysis
of two randomized, controlled clinical trials in which the
safety and efficacy of LPV/r QD (800/400 mg) versus
twice-daily (400/100 mg) doses were compared in treat-
ment-naïve patients [9-11]. Abbott Study 418 evaluated
LPV/r SGC QD versus BID dosing and showed an increase
in the incidence or severity of GI side effects for QD com-
pared with the BID regimen [11]. This is in contrast to the
findings of the largest study of LPV/r tablet formulation,
Abbott Study 730, where LPV/r SGC QD and BID dosing
were compared to LPV/r tablet QD and BID dosing in 664
subjects [5]. Abbott Study 730 concluded that QD and
BID dosing have similar overall safety and tolerability. In
our study, respondents that were switched from LPV/r
SGC to QD LPV/r tablet reported increased satisfaction
and tolerability after switching to the QD regimen regard-
less of whether the pre-switch SGC regimen was dosed
QD and BID. There were greater improvements reported
by survey respondents switching from the QD SGC regi-
men to the QD tablet regimen [5].
Lower mean LPV trough concentrations were reported in
Abbott Study 056 and Study 418 with LPV/r 800/200 mg
QD dosing (3.62 mcg/mL and 4.37 mcg/mL, respectively)
compared to LPV/r 400/100 mg BID dosing [10,11].
However, antiretroviral activity was not affected. A recent
analysis of 5 clinical trials of LPV/r dosed QD and BID
concluded that there is no significant association between
mean LPV trough concentration and virologic response in
naïve patients [12]. Additionally, trough LPV concentra-
tions < 1 mcg/mL were not associated with virologic fail-
ure. Currently, QD dosing of LPV/r is not recommended
for treatment-experienced patients due to a lack of clinical
safety and efficacy data. However, the efficacy and safety
of LPV/r QD versus LPV/r BID in treatment-experienced
patients is currently being investigated in Abbott Study
802, a large, randomized 48-week clinical trial [13].
Previous studies of antiretroviral choice have shown that
patients find lack of side effects more important than con-
venience (e.g. pill count, dosing frequency, etc.) and this
may impact adherence [14,15]. In this study, reduction in
side effects impacted patient-reported adherence. When
patients switched from SGCs to tablets, adherence (as
assessed by number of self-reported missed doses per
week and the number of respondents who indicated "not
missing doses in the last week") improved and signifi-
cantly fewer respondents cited "avoiding side effects" as a
reason for non-adherence. An analysis of adherence rates
by ethnic groups with LPV/r tablet has not been reported
previously. Importantly, Hispanic and Black respondents
reported significantly improved adherence. Racial differ-
ences in non-adherence in order to "avoid side effects"
were no longer evident after the formulation switch.
In addition to reducing GI side effects, the tablet formula-
tion provides greater convenience because it reduces the
pill count (four tablets per day as opposed to six SGCs),
can be tolerated as a QD regimen, and does not need to be
refrigerated. Also, while the SGC has to be taken with food
for adequate bioavailability, there is limited effect of food
on LPV pharmacokinetics with the tablet formulation [3].
The vast majority of respondents (88% of those who
switched to a BID regimen and 93% of those who
switched to a QD regimen) preferred the tablet to the SGC
because of these factors. Seventy-five percent of respond-
ents who switched to the QD regimen indicated they
"liked" taking LPV/r just once a day. Another reason for
greater patient preference for the tablet formulation is
improvement in quality of life, observed in 73% of
respondents after switching from SGCs to tablets.
While our sample did not include adequate numbers of
females for a meaningful analysis of gender differences,
the effect of gender on the safety and efficacy of LPV/r was
evaluated in Abbott Study 730. Similar rates of moderate
or severe diarrhea, nausea, and vomiting were observed
for males and females [16]. Abbott Study 730 also evalu-
ated the safety of LPV/r tablets in whites versus non-whites
and reported that moderate or severe diarrhea rates were
similar for whites and the overall study population, whileAIDS Research and Therapy 2008, 5:21 http://www.aidsrestherapy.com/content/5/1/21
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non-whites rates were lower [17]. Our study compared
more ethnic groups (Caucasians, Blacks, and Hispanics)
and also included a comparison of LPV/r SGC to tablet.
Tolerability and satisfaction were found to significantly
improve across all ethnic groups (Hispanic, Black, and
Caucasian) with the switch to LPV/r tablets. The rates of
"severe" diarrhea were reduced in all ethnic groups with
Caucasians having the greatest reduction in antidiarrheal
use.
We are aware that this study is based on market research
and that the survey used is not a validated instrument or
quality of life measure. However, it does provide informa-
tion regarding patient perceptions and preferences of LPV/
r therapy.
Conclusion
It is clear from this study that patients prefer the new LPV/
r tablet formulation due to improvements in side effects
and greater convenience. Further studies are required to
prospectively compare the LPV/r tablet formulation with
other drug regimens. Until now, all clinical trial compari-
sons versus other PIs and EFV have been made with LPV/r
SGC [18-23]. Emerging data from the TITAN and CASTLE
studies include a mixture of LPV/r SGC and tablet due to
the studies being started prior to LPV/r tablet receiving
FDA approval. In the ARTEMIS study, only 2% of patients
solely used LPV/r tablets, so further data to discern tolera-
bility differences between other PIs, EFV, and LPV/r tab-
lets are still needed [24-26].
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